logo-loader
HealthPharma & Biotech
ANGLE PLC

ANGLE passes key milestone recruitment is completed for phase III clinical trial of its liquid biopsy system

A total of 400 people will with late-stage breast cancer will be screened using the Parsortix system, which harvests tumour cells

researcher using microscope
Results from the trial will be submitted to the Food & Drug Administration by mid-year as planned

ANGLE PLC (LON:AGL, OTCQX:ANPCY) said it had passed a “key milestone” following the completion of recruitment to a phase III clinical study to assess the potential of its liquid biopsy in metastatic breast cancer.

A total of 400 people will be screened using the Parsortix system, which harvests tumour cells. The work is being carried out at world-leading cancer centres in Texas, California and Illinois.

READ: “Significant milestone” for ANGLE as it kicks off second ovarian cancer study

Results from the trial will be submitted to the Food & Drug Administration by mid-year as planned.

However, ANGLE cautioned that the timeline, once the FDA has received all the data, is uncertain as researchers are following a completely new protocol for an entirely unique product – in other words, the regulator doesn’t have an established blueprint or tick-sheet to follow.

Chief executive Andrew Newland said: “We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis, in the first instance for metastatic breast cancer."

Quick facts: ANGLE PLC

Price: £0.71

Market: AIM
Market Cap: £122.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read